Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

New Lung Cancer Treatment Approved in Japan Offers Hope

People in Japan with a specific type of lung cancer have a new treatment option. The Japanese Ministry of Health, Labour and Welfare recently approved Tagrisso (osimertinib) in combination with chemotherapy. This is big news for patients with EGFR-mutated advanced lung cancer who haven’t received any treatment yet.

EGFR-mutated lung cancer is a type of lung cancer where cancer cells have a specific mutation, making them grow quickly. Tagrisso is a targeted therapy drug that works by blocking the signals from the EGFR mutation, slowing down cancer growth.

This approval was based on a large study that showed promising results. The study found that Tagrisso, along with chemotherapy, significantly slowed down the progression of the cancer compared to chemotherapy alone. This means patients could live longer without their disease worsening.

This new treatment combination offers hope for patients and their families. It provides a new first-line treatment option, meaning it’s the first treatment patients will receive after diagnosis. Doctors are optimistic that this approval will lead to better outcomes for people in Japan battling this specific type of lung cancer.